Skip to main content

Table 2 Clinical, functional, and laboratory data at baseline and at 3 and 6 months of treatment

From: Real-life experience with benralizumab during 6 months

Variables BaselineMean (SD) 3 months Mean (SD) 6 months Mean (SD) p*
ACT 13.9 (4.1) 20.1 (3.7) 21 (2.7) < 0.001
Patients with controlled asthma (ACT≥20) 2 (4.8) 24 (57.1) 34 (81) < 0.001
No. of ED visits per quarter, median (interquartile range) 1 (IR:0.7) 0 (IR:0.75) 0 (IR:0) < 0.001
Corticosteroid-dependent, n (%) 16 (40%) 15 (35.7%) 8 (19%) 0.008
Inhaled budesonide (or equivalent) dose, μg/day 956 (475) 802 (415) 714 (356) 0.001
Oral prednisone dose, mg/day 19.6 (9) 7.5 (8.6) 5 (7.9) 0.007
Cycles of OCS per quarter, median (interquartile range) 1.5 (IR:1.25) 0 (IR:1) 0 (IR:0) < 0.001
FEV1 mL 1429.4 (475) 1680 (481) 1721 (610) < 0.001
FEV1% 64.3 (9.3) 73.1 (9.1) 76 (12) < 0.001
FeNO 61.5 (23.9) 30.6 (14.6) 27.8 (14.9) < 0.001
Blood eosinophil count, cells/μL 757.2 (278) 18.9 (18) 15.2 (13.6) < 0.001
  1. * Comparison between data at baseline and at 6 months
  2. Abbreviations: ACT Asthma Control Test, BD Bronchodilator, BMI Body mass index, ED Emergency department, FeNO Fractional exhaled nitric oxide, FEV1 Forced expiratory volume in 1 s, OCS Oral corticosteroids, SD Standard deviation